polyneuropathy

The drug treats a progressively fatal neurodegenerative condition, transthyretin familial amyloid polyneuropathy, that is currently treated by liver transplant.

Pfizer Sells Capsugel Unit to KKR for $2.38 Billion Jonathan D. Rockoff 2011

Chronic inflammatory demyelinating polyneuropathy CIDP

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

If such a plan succeeded, one could theoretically repair the damaged nerves in MS, transverse myelitis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and acute disseminated encephalomyelitis—all neurological autoimmune diseases in which the myelin sheaths and axonal nerves are compromised.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

If such a plan succeeded, one could theoretically repair the damaged nerves in MS, transverse myelitis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and acute disseminated encephalomyelitis—all neurological autoimmune diseases in which the myelin sheaths and axonal nerves are compromised.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

Chronic inflammatory demyelinating polyneuropathy CIDP

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

-- An increased risk of polyneuropathy (nerve damage that causes pain in the hands and feet and trouble walking) -- Dizziness

The Cholesterol Myth That Could Be Harming Your Health 2010

-- An increased risk of polyneuropathy (nerve damage that causes pain in the hands and feet and trouble walking) -- Dizziness

Dr. Joseph Mercola: The Cholesterol Myth That Could Be Harming Your Health 2010

FoldRx's drug treats a disease called TTR amyloid polyneuropathy and has orphan-drug status designed to encourage drugmakers to develop treatments for rare diseases in the U.S. and European Union, as well as fast-track designation in the U.S. Geno Germano, head of Pfizer's specialty-care business, said the acquisition will add to its growing portfolio of investigational drugs for orphan and rare diseases and complement research in the specialty-care unit's neuroscience disease area.

Pfizer Agrees to Acquire Drug Developer FoldRx 2010